Immunocyte cell therapy can be divided into immunomodulators, vaccines, immune cell defects and cancer cell blocking, and MTCA-CLT. MTCA-CLT is a state-of-the-art therapy with 5th generation immunotherapy.

Immunomodulators are used to treat cancer cells by increasing the specific immune response to substances that cause cancer cells or cancer cells and by increasing immunity to existing antigens. These include Interferon, interleukin-2, Thymosin Alpha-1, Thymosin alpha, lentinan, Polyporus Polysacharide, and zymosan. Tumor vaccine therapy uses tumor cells or tumor antigen materials to induce specific immunity and humoral immunity of organisms to enhance the antitumor ability of the organism and prevent tumor metastasis and recurrence. Tumor vaccines include: peptide vaccination, nucleic acid vaccine, recombinant virus vaccine, bacterin vaccine, and DC vaccination. Immunocellular defects and cancer cell blocking technology are antibodies to T lymphocyte antigen 4 (CTLA-4) (lpilimumab) and antibodies against other CD8-positive T cells (PD1 / PD-L1) .

The MTCA-CTL immunotherapy is based on the biological features of tumors as an improvement of tumor therapy technology. Through the study of biological features of the tumor, the cell immunotherapy can be applied to 2nd generation CLK cells, 3rd generation DC-CIK cells as non- Are represented. The fourth generation DC-CIK-specific immune cells in the current developmental stage have evolved continuously in the area of ​​cellular immunity. MTCA-CTL was developed with 5th generation immune cell technology. Non-MHC-restricted killer NK-T cells were expanded and MHC-restricted CD8 + specific CTL cells were cultured to reach 60-70% in conventional cultures. The function of the two kinds of killing cells has been improved. 

The merits of MTCA-CTL are safe, effective, and non-toxic. Immune cell therapy uses the patient's own immune cells for treatment, and it has less serious side effects, except for mild fever side effects, so the patient's body is less burdensome. By adding a large number of specific antigens to the existing MTCA-CTL immunotherapy method, it can kill more precise targets and induce long-term and efficient tumor activity by replication of immune cells. Based on the existing MTCA-CTL immunotherapy, 200 ~ 1000 times of cell culture will increase killing effect by 10 billion cell increase. MTCA-CTL immunotherapy can be used 48 hours after chemotherapy. Increase immunity, reduce the side effects of chemotherapy, and strengthen it step by step to get the best treatment effect.